Thelansis

 Patients with Non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation constitute a distinct cohort. Their cancer's etiology, clinicopathological characteristics, prognosis, and treatment approaches diverge from other NSCLC patients. EGFR mutations manifest in approximately 40%–60% of Southeast Asian individuals or 10%–20% of Caucasians diagnosed with lung adenocarcinomas. While prevalent among non-smokers or light smokers, EGFR mutation-positive tumors may also occur in other smoking profiles. Notably, the rise in non-smoking habits has led to a higher proportion of female patients exhibiting EGFR mutations compared to males. In the Iressa Pan Asian Survival Study (IPASS) trial, which enrolled Asian non-smokers or non-smokers with lung adenocarcinoma, females constituted 80% of the participant pool.   Thelansis’s “EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 ...